Details of the Drug Combination

General Information of Drug Combination (ID: DCBKJYY)

Drug Combination Name
Valrubicin Topetecan
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs Valrubicin   DMOYJFK Topetecan   DMAE6LK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: HCT116
Zero Interaction Potency (ZIP) Score: 1.22
Bliss Independence Score: 0.36
Loewe Additivity Score: 0.29
LHighest Single Agent (HSA) Score: 3.52

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Valrubicin
Disease Entry ICD 11 Status REF
Bladder cancer 2C94 Approved [2]
In situ carcinoma N.A. Approved [3]
Urinary bladder cancer N.A. Approved [3]
Psoriasis vulgaris EA90 Phase 2 [4]
Valrubicin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Valrubicin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [7]
------------------------------------------------------------------------------------
Indication(s) of Topetecan
Disease Entry ICD 11 Status REF
Small-cell lung cancer 2C25.Y Approved [5]
Topetecan Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DCRXOVT HL-60(TB) Investigative [9]
Adult T acute lymphoblastic leukemia DCJ0W9Z MOLT-4 Investigative [9]
Anaplastic large cell lymphoma DCR2ZGS SR Investigative [9]
Astrocytoma DCI4FS6 U251 Investigative [9]
Childhood T acute lymphoblastic leukemia DC691R1 CCRF-CEM Investigative [9]
Invasive ductal carcinoma DCFEDRA T-47D Investigative [10]
Adenocarcinoma DCK7RJA DU-145 Investigative [1]
Adenocarcinoma DCQJ14A NCIH23 Investigative [1]
Adenocarcinoma DCM5MW2 A549 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 Valrubicin FDA Label
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
6 Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II. NCI Monogr. 1987;(4):111-5.
7 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
8 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
9 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
10 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.